Kim SH, et al. - This study proposed and tested a simplified protocol using rituximab and intravenous immunoglobulin (IVIG) for ABO-incompatible (ABO-I) living donor liver transplantation (LDLT). Findings demonstrated the safety of this simplified protocol as well as its efficacy in achieving sufficient desensitization and comparable outcomes in patients with the titer no higher than 1:64.